TN2011000262A1 - Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid - Google Patents

Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid

Info

Publication number
TN2011000262A1
TN2011000262A1 TN2011000262A TN2011000262A TN2011000262A1 TN 2011000262 A1 TN2011000262 A1 TN 2011000262A1 TN 2011000262 A TN2011000262 A TN 2011000262A TN 2011000262 A TN2011000262 A TN 2011000262A TN 2011000262 A1 TN2011000262 A1 TN 2011000262A1
Authority
TN
Tunisia
Prior art keywords
ethyl
trifluoromethyl
cyclohexyl
benzyl
carboxylic acid
Prior art date
Application number
TN2011000262A
Other languages
French (fr)
Inventor
La Cruz Marilyn De
Piotr H Karpinski
Michael Mutz
Christian Riegert
Caspar Vogel
Ricardo Schneeberger
Lech Ciszewski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to TN2011000262A priority Critical patent/TN2011000262A1/en
Publication of TN2011000262A1 publication Critical patent/TN2011000262A1/en

Links

Abstract

This invention relates to a hemifumarate salt of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of the hemifumarate salt form of Compound I, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.
TN2011000262A 2011-05-23 2011-05-23 Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid TN2011000262A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TN2011000262A TN2011000262A1 (en) 2011-05-23 2011-05-23 Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TN2011000262A TN2011000262A1 (en) 2011-05-23 2011-05-23 Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid

Publications (1)

Publication Number Publication Date
TN2011000262A1 true TN2011000262A1 (en) 2012-12-17

Family

ID=54696173

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000262A TN2011000262A1 (en) 2011-05-23 2011-05-23 Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid

Country Status (1)

Country Link
TN (1) TN2011000262A1 (en)

Similar Documents

Publication Publication Date Title
JO2894B1 (en) New salt and crystalline forms
IL260297A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
UA110310C2 (en) Compounds n-aryl triazole as antagonists receptors lisophosphatidic acid (lpar)
NZ708501A (en) Treatment of pulmonary disease
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
MX343753B (en) Neprilysin inhibitors.
JO3510B1 (en) Use of glycopyrrolate for treating tachycardia
PH12015501239A1 (en) Oral care products comprising tetrabasic zinc chloride and trimethylglycine
UA109867C2 (en) Substituted pyrazole compounds as antagonists lysophosphatidic acid receptors (lpar)
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
PH12018501575A1 (en) Indolinones compounds and their use in the treatment of fibrotic diseases
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
EA201391586A1 (en) 17α-HYDROXYLASE / C-LIAZ INHIBITORS
TN2011000262A1 (en) Hemifumarate salt of 1-[4-(cyclohexyl-3-trifluoromethyl-benzyloxymino)-ethyl]-2-ethyl-benzyl]-a zetidine-3-carboxylic acid
MX2015006807A (en) METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)- N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXA MIDE AND CRISTAL FORMS THEREOF.
TN2013000023A1 (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases